NASDAQ:LSTA Lisata Therapeutics Q4 2025 Earnings Results & Report $1.07 +0.05 (+4.90%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.07 0.00 (0.00%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lisata Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$0.33 versus the -$0.74 consensus estimate, while revenue was $0.10 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market Opens Lisata Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.74Beat/MissBeat by +$0.41One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersLisata Therapeutics Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsLisata Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Lisata Therapeutics Q4 2025 Earnings FAQ Did Lisata Therapeutics beat earnings estimates for Q4 2025? Lisata Therapeutics (NASDAQ:LSTA) reported earnings of -$0.33 per share for Q4 2025, beating the consensus estimate of -$0.74. The report was announced on Thursday, March 12, 2026. What was Lisata Therapeutics' revenue for Q4 2025? Lisata Therapeutics reported revenue of $0.10 million for Q4 2025. When is Lisata Therapeutics' next earnings date? Lisata Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lisata Therapeutics on the company's earnings history page. Lisata Therapeutics Earnings HeadlinesLisata adds biopharma finance veteran Jeffrey Farrow to boardOctober 15 at 8:59 AM | proactiveinvestors.comReviewing Dyadic International (NASDAQ:DYAI) & Lisata Therapeutics (NASDAQ:LSTA)October 15 at 2:15 AM | americanbankingnews.comOn Oct 15, AI Could Make Life Very Strange in AmericaWall Street veteran Marc Chaikin, who called the 2020 market crash, says a major shift could unfold starting October 15. Chaikin, a frequent CNBC Mad Money guest whose trades Jim Cramer has long tracked, says the next phase of the AI boom could reshape how ordinary investors build wealth. He has agreed to share his Hotlist and Hitlist of stocks to buy and sell, free of charge, ahead of the date. | Chaikin Analytics (Ad)Lisata Therapeutics, Inc. Announces Appointment of Jeffrey Farrow as Class III Director and Audit Committee Member, Effective October 13, 2026October 14 at 10:13 PM | marketscreener.comMLisata Therapeutics Expands Board, Appoints Independent DirectorOctober 14 at 4:51 PM | tipranks.comLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsOctober 14 at 4:05 PM | globenewswire.comSee More Lisata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email. Email Address About Lisata TherapeuticsLisata Therapeutics (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies intended to improve the treatment of solid tumors. The company’s approach centers on tumor-penetrating peptides designed to selectively target the tumor microenvironment and help therapeutic agents reach cancer cells more effectively. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is designed to activate the CendR pathway, which may increase the penetration and distribution of co-administered anticancer treatments within tumors. The company has studied certepetide in combination with chemotherapy and other cancer therapies, including in pancreatic cancer and other advanced solid tumors. The product remains investigational and is not approved for commercial use. The company was formerly known as Cend Therapeutics and adopted the Lisata Therapeutics name in 2022. Its development programs are conducted through collaborations and clinical studies involving research institutions, biotechnology companies and pharmaceutical partners in the United States and other regions. Lisata is headquartered in San Diego, California, and is led by President and Chief Executive Officer David J. Mazzo.View Lisata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
